Article ISI
ANNALS OF ONCOLOGY  (2020)

Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study

Moehler, M.; Yamaguchi, K.; Skoczylas, T.; Campos Bragagnoli, A.; Yanez, P.; Tehfe, M.; Poulart, V.; Ajani, J. A.; Janjigian, Y. Y.